The European Cubicin(R) Outcomes Registry and Experience (EU-CORE[SM]), a non-interventional, multicenter, observational registry in patients receiving at least one dose of daptomycin between January 2006 and April 2012.

Trial Profile

The European Cubicin(R) Outcomes Registry and Experience (EU-CORE[SM]), a non-interventional, multicenter, observational registry in patients receiving at least one dose of daptomycin between January 2006 and April 2012.

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2016

At a glance

  • Drugs Daptomycin (Primary)
  • Indications Bacteraemia; Gram-positive infections; Skin and soft tissue infections
  • Focus Therapeutic Use
  • Acronyms EU-CORE
  • Sponsors Novartis Pharma
  • Most Recent Events

    • 12 Apr 2016 Results of pooled analysis of CORE and EU-CORE registries (n=11557) presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
    • 03 Feb 2016 Results from subgroup analysis of children and adolescent patients (n = 81) published in the Pediatric Infectious Disease Journal.
    • 26 Nov 2015 Results (n=5989) comparing high dose safety and effectiveness with licensed doses published in the Advances in Therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top